Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | ARHGDIA | P52565 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 8/20 | 0.43 |
| ▸ | DRD3 | P35462 | 8/20 | 0.43 |
| ▸ | DRD1 | P21728 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9678342 | 0.88 | SIGMAR1 (0.45) | GBA1ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL5833647 | 0.84 | ROCK2 (0.45) | ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL4966861 | 0.81 | MAPT (0.50) | GBA1ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL6545137 | 0.81 | SIGMAR1 (0.44) | ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL5833930 | 0.80 | ROCK2 (0.42) | ROCK2ARHGDIAROCK1MAPT | |
| Hydrochloric Acid SCHEMBL6707460 | 0.80 | SIGMAR1 (0.43) | ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL6180409 | 0.79 | KDM4E (0.44) | ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL4198217 | 0.79 | FUCA1 (0.54) | GBA1DRD2DRD3 | |
| SCHEMBL5833935 | 0.79 | ROCK2 (0.41) | ROCK2ARHGDIAROCK1MAPT | |
| SCHEMBL5833927 | 0.79 | ROCK2 (0.43) | ROCK2ARHGDIAROCK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217596-B1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | MERCK SHARP & DOHME (US) | 2013-01-30 | — | — | EP | disclosed |
| US-7008955-B2 | (2-azabicyclo[2.2.1]hept-7yl) methanol derivatives as nicotinic acetylcholine receptor agonists | MERCK PATENT GMBH (DE) | 2006-03-07 | — | — | US | disclosed |
| EP-1317430-B1 | (2-AZABICYCLO [2.2.1]HEPT-7-YL)METHANOL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | MERCK PATENT GMBH (DE) | 2005-05-18 | — | — | EP | disclosed |
| US-20040110788-A1 | Nicotinic acetylcholine receptor ligands | MERCK PATENT GMBH (DE) | 2004-06-10 | — | — | US | disclosed |
| US-20040039045-A1 | (2-azabicyclo[2.2.1]hept-7yl) methanol derivatives as nicotinic acetylcholine receptor agonists | MERCK PATENT GMBH (DE) | 2004-02-26 | — | — | US | disclosed |
| EP-1379502-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | MERCK PATENT GmbH (DE) | 2004-01-14 | — | — | EP | disclosed |
| EP-1317430-A1 | (2-AZABICYCLO 2.2.1]HEPT-7-YL)METHANOL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | MERCK PATENT GmbH (DE) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002083640-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | MERCK PATENT GMBH (DE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002022578-A1 | (2-AZABICYCLO[2.2.1]HEPT-7-YL)METHANOL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | MERCK PATENT GMBH (DE) | 2002-03-21 | — | — | WO | disclosed |
| US-5397800-A | Gastrointestinal disorders | PFIZER INC. (US) | 1995-03-14 | — | — | US | disclosed |
| EP-0510129-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | Pfizer Limited (GB) | 1992-10-28 | — | — | EP | disclosed |
| WO-1992005172-A2 | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 1992-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039045-A1 | (2-azabicyclo[2.2.1]hept-7yl) methanol derivatives as nicotinic acetylcholine receptor agonists | CHRNA1, CHRNA10, CHRNB1 | GBA1 2526/4885ROCK2 2739/4885ARHGDIA 1117/4885 |
| US-20040110788-A1 | Nicotinic acetylcholine receptor ligands | CHRNA1, CHRNA2, CHRNA10 | GBA1 526/4885ROCK2 2334/4885ARHGDIA 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.